Hui-Yi Lin

Title:
Associate Professor & Graduate Coordinator

Department:
Biostatistics

Office:
LEC 265

Telephone:
504-568-6083

Email:
hlin1@lsuhsc.edu

CV:
HLIN1.CV.PDF

Software

 

Biography & Expertise

Education

PhD Biostatistics Tulane University 2004
MS Biostatistics University of Michigan 2001
MS Health Behavior National Taiwan University 1996
BA Public Health National Taiwan University 1994

Selected Publications

Katner, A. L., Pieper, K., Brown, K., Parks, J., Hu, C., Lin, H., Wang, X., & Edwards, M. (2017, August). Evaluation of Waterborne Lead Levels in New Orleans, LA: Policy Implications for Monitoring and Exposure Reduction. , 27(8), 513.
Wu, E. S., Park, J. Y., Zeitouni, J. A., Gomez, C. R., Reis, I. M., Zhao, W., Kwon, D., Lee, E., Nelson, O. L., Lin, H., Franzmann, E. J., Savell, J., McCaffrey, T. V., Goodwin, W. J., & Hu, J. J. (2016, August). Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis. , 38(8), 1234-41.
Menezes, L. J., Poongulali, S., Tommasino, M., Lin, H., Kumarasamy, N., Fisher, K. J., Saravanan, S., Gheit, T., Ezhilarasi, C., Jeeva, A., Lu, B., & Giuliano, A. R. (2016, June). Prevalence and concordance of human papillomavirus infection at multiple anatomic sites among HIV-infected women from Chennai, India. , 27(7), 543-53.
Das, D. K., Osborne, J. R., Lin, H., Park, J. Y., & Ogunwobi, O. O. (2016, June). miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. , 9(3), 236-41.
Nyitray, A. G., da Carvalho Silva, R. J., Chang, M., Baggio, M. L., Ingles, D. J., Abrahamsen, M., Papenfuss, M., Lin, H., Salmerón, J., Quiterio, M., Lazcano-Ponce, E., Villa, L. L., & Giuliano, A. R. (2016, June). Incidence, Duration, Persistence, and Factors Associated With High-risk Anal Human Papillomavirus Persistence Among HIV-negative Men Who Have Sex With Men: A Multinational Study. , 62(11), 1367-1374.
Baz, R. C., Martin, 3rd, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A., Chari, A., Sullivan, D. M., Nardelli, L. A., Lau, K., Alsina, M., & Jagannath, S. (2016, May). Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. , 127(21), 2561-8.
Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., Baz, R., Korde, N., Lin, H., Chen, J. Q., Herrmann, M., Xi, L., Raffeld, M., Zhao, X., Wan, W., Tombes, M. B., Shrader, E., Weir-Wiggins, C., Sankala, H., Hogan, K. T., Doyle, A., Annunziata, C. M., Wellons, M., Roberts, J. D., Sullivan, D., Landgren, O., & Grant, S. (2016, March). A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. , 22(5), 1067-75.
Winham, S. J., Pirie, A., Chen, Y. A., Larson, M. C., Fogarty, Z. C., Earp, M. A., Anton-Culver, H., Bandera, E. V., Cramer, D., Doherty, J. A., Goodman, M. T., Gronwald, J., Karlan, B. Y., Kjaer, S. K., Levine, D. A., Menon, U., Ness, R. B., Pearce, C. L., Pejovic, T., Rossing, M. A., Wentzensen, N., Bean, Y. T., Bisogna, M., Brinton, L. A., Carney, M. E., Cunningham, J. M., Cybulski, C., deFazio, A., Dicks, E. M., Edwards, R. P., Gayther, S. A., Gentry-Maharaj, A., Gore, M., Iversen, E. S., Jensen, A., Johnatty, S. E., Lester, J., Lin, H., Lissowska, J., Lubinski, J., Menkiszak, J., Modugno, F., Moysich, K. B., Orlow, I., Pike, M. C., Ramus, S. J., Song, H., Terry, K. L., Thompson, P. J., Tyrer, J. P., van den Berg, D. J., Vierkant, R. A., Vitonis, A. F., Walsh, C., Wilkens, L. R., Wu, A. H., Yang, H., Ziogas, A., Berchuck, A., Chenevix-Trench, G., Schildkraut, J. M., Permuth-Wey, J., Phelan, C. M., Pharoah, P. D., Fridley, B. L., Sellers, T. A., & Goode, E. L. (2016, March). Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. , 25(3), 446-54.
Earp, M., Winham, S. J., Larson, N., Permuth, J. B., Sicotte, H., Chien, J., Anton-Culver, H., Bandera, E. V., Berchuck, A., Cook, L. S., Cramer, D., Doherty, J. A., Goodman, M. T., Levine, D. A., Monteiro, A. N., Ness, R. B., Pearce, C. L., Rossing, M. A., Tworoger, S. S., Wentzensen, N., Bisogna, M., Brinton, L., Brooks-Wilson, A., Carney, M. E., Cunningham, J. M., Edwards, R. P., Fogarty, Z. C., Iversen, E. S., Kraft, P., Larson, M. C., Le, N. D., Lin, H., Lissowska, J., Modugno, F., Moysich, K. B., Olson, S. H., Pike, M. C., Poole, E. M., Rider, D. N., Terry, K. L., Thompson, P. J., van den Berg, D., Vierkant, R. A., Vitonis, A. F., Wilkens, L. R., Wu, A. H., Yang, H. P., Ziogas, A., Phelan, C. M., Schildkraut, J. M., Chen, Y. A., Sellers, T. A., Fridley, B. L., & Goode, E. L. (2016, February). A targeted genetic association study of epithelial ovarian cancer susceptibility. , 7(7), 7381-9.
Tseng, T., Lin, H., Griffiths, L., Cornwell, K., & Sothern, M. (2016, October (4th Quarter/Autumn)). Sugar intake from sugar-sweetened beverage among cancer and non-cancer individuals: the NHANES study. AME Publishing Company, 5(S5), S1019-S1028.